In a post-hoc study of patients with HER2 immunohistochemical scores of 3+ or 2+ and fluorescence in situ hybridisation-positive tumours, trastuzumab in combination with chemotherapy improved the median overall survival compared with chemotherapy alone (16.0 versus 11.8 months, respectively) (48). The gene discussed is ERBB2; the disease is neoplasm.